Introduction
Elimination of disparities in health and health care are extremely high public health priorities in the US, 1 but Neurology lags behind other medical specialties in such research. 2 As with other chronic diseases, epilepsy is impacted by various social, economic and cultural factors. However, research on the role of socio-demographic factors such as race/ethnicity, gender, age, and insurance status on medical treatment and outcomes in people with epilepsy (PWE) is lacking, and at times conflicting. 3, 4 Epidemiologic studies have shown higher rates of epilepsy in African-Americans and Hispanics compared to non-Hispanic Caucasians. 5, 6 African-Americans have been noted to be less likely to receive anti-epileptic drugs (AEDs), 7 or be compliant with AEDs prescribed, [8] [9] [10] and more likely to have visits to generalists 11 and Emergency Rooms 9, 11 or to be hospitalized. 11, 12 African-Americans are also less likely to undergo epilepsy surgery. 13, 14 Status epilepticus 15 and age-adjusted mortality due to epilepsy were also found to be higher in black patients. 16 One study looking into the underlying causes of racial disparity in epilepsy found four major obstacles to optimal care: limited financial resources, lack of knowledge about epilepsy, poor patient-provider communication, and lack of social support. 17 The findings of disparity in epilepsy are not surprising in the context of similar socio-demographic disparity reported in other chronic conditions such as asthma, [18] [19] [20] end-stage renal disease, 21 cancer, 22, 23 invasive pneumonia, 24 and bariatric surgery 25 among others. On the other hand, there also exists literature which has failed to find racial disparity in epilepsy epidemiology, care or outcomes. In contrast to the abovementioned reports, some epidemiologic studies did not find a racial difference in the incidence of epilepsy. 26, 27 A recent study found increased generalist and emergency room visits among African-Americans compared to Caucasians, and among lowerincome compared to higher income PWE, but these effects were seen to be dependent on the center in this multi-center study: controlling for the center in the statistical model negated the significance of these findings.
Methods
The study was approved by the Institutional Review Board at the Drexel University College of Medicine (DUCOM), and was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki. Written informed consent was not deemed necessary for this retrospective chart review.
Recruitment and data collection
The clinic charts of all patients aged 18 and older attending the epilepsy clinic at Drexel University College of Medicine, Philadelphia between 2008 and 2010 were reviewed. A cross-sectional analysis of prevalent cases of epilepsy on anti-epileptic medications was performed. Patients without a clear history of epilepsy, possible non-epileptic seizures or syncope, migraines and patients not on antiepileptic drugs were excluded. Race information was abstracted from the clinical record demographics as self-identified by the patients. Data on race is routinely collected as part of the outpatient demographics at Drexel University. Patients belonging to races other than non-Hispanic Caucasians and African-Americans were also excluded as the numbers were too small for meaningful sub-group analyses. Data collected included age, gender, race, insurance type, current AED, home zip code, age at seizure onset, duration of epilepsy, and seizure control as represented by seizure frequency. The data collected was from the demographic information of the medical record and from the progress note of the treating epileptologist. Ultimately, 193 patients were included for statistical analyses. The primary objective of this study was to determine whether socioeconomic factors specifically race, gender, household income, cost of medications and insurance status are associated with epilepsy control.
Data coding and calculations
Seizure control as documented in the clinical notes was coded as 'good control' if there were no seizures in the one year prior to clinic visit, and as 'poor control' otherwise in line with previous research. 28 As has been done in previously published health outcomes research, the median household income of patients were calculated from the US census data (2000) of race-specific median household income compared to the patient's zip code. 18, 19 Following the methodology of previous research, we calculated the cost of medications based on the generic price for an estimated median dose of AED (available from drugstore.com, Table 1 ). 29 
Statistical analysis
To assess the impact of socio-demographic variables on treatment outcomes (good vs. poor seizures control) and race (Caucasian vs. African-American), chi-squared tests (for gender, insurance status) and t-tests (for age, household income, cost of medications) were used. To examine the effect of race-independent income on seizure control, the incomes of all patients were divided into quartiles and compared to the medication costs using ANOVA. Logistic regression of the variables was performed for multi-variable analysis. Statistical analyses were performed using PASW Statistics, Release Version 19.0.0 (SPSS, Inc., 2010, Chicago, IL, www.spss.com).
Results
Of the 193 records analyzed, there were 120 females and 73 males with a mean age of 47.8 AE 16.5 years.
Seizure control and socio-demographic variables
The different socio-demographic and health related variables were compared to seizure control (Table 2 ) and are detailed below.
Race
There were 124 African Americans and 69 Caucasians included in the analyses. Good seizure control was found in 68 patients (35.2%) and poor seizure control in 125 patients (64.8%). Race did not impact seizure control (x2 test, p = 0.18; odds ratio 1.54 [C.I: 0.82-2.92]).
Household income
The household income was not significantly different between patients with good control and those with poor control. Racespecific differences in income and seizure control are detailed below (''Race and socio-demographic/outcome variables''). To examine the effect of race-independent household income on seizure control, the family income of all patients were divided into quartiles of income and seizure control compared between the groups (data not shown). There was no significant difference in seizure control between different race-independent income groups (x 2 test, p = 0.75).
The median household income (AESD) for patients with Medicare ($35,928 AE $13,614), Medicaid ($32,929 AE $11,741) or Private insurance ($32,520 AE $14,057) were not significantly different (ANOVA p = 0.49).
AEDs
Poor seizure control was associated with the use of more AEDs ( Figure 1A . x2 test, p = 0.03) and a non-significant trend toward higher cost of medications (p = 0.06). However, the higher cost was likely contributed by outliers as a box and whisker plot showed similar distribution of medication costs between the two groups with a smaller number of patients in the poor control group having a higher medication cost ( Figure 1B) . The total cost of AEDs did not change as a function of insurance type (p = 0.60).
Race and socio-demographic/outcome variables
The income for African Americans was significantly lower than Caucasians in line with the national census data. The median household income for Caucasians in our group ($44,136) was similar to the national average household income for Caucasians ($44,687) in the 2000 census. The median household income for African-Americans ($26,935) was lower than the national average 
Multivariate analysis
Multivariate regression of the various variables (gender, insurance status, household income, age, medication cost and race) against seizure control (poor v. good control) revealed a trend for higher medication costs to be associated with poor seizure control (p = 0.06). The other variables did not reveal significant difference based on seizure control.
Discussion
We evaluated a unique inner-city population consisting of both Caucasian and African-American PWE to determine if socioeconomic factors such as race, gender, household income, cost of medications or insurance status are associated with epilepsy control. Our analysis did not reveal an effect of race, gender, household income or insurance type on seizure control.
Control of epilepsy was worse in our study (64.8%) compared to a previous study (40.8%) which used similar criteria to define good seizure control 28 and from other previous reports (30-40%) of pharmacoresistant epilepsy. 30, 31 This was thought to be due to the more severe cases of epilepsy that get referred to our specialist clinic from the General Neurology practice in our hospital and from outside referrals.
Race and family income
Previous research in epilepsy has found a significant difference in control of disease based on race 9, 11, 12 or income. 11 In our group, we found that Caucasians and African-American PWE have similar seizure control, although family income was lower for AfricanAmericans. The incidence of epilepsy has been reported to be higher in African-Americans. 6 African-American patients are more likely to be under-treated, have subtherapeutic AED levels and attend the Emergency Room more frequently. 7, 9, 11, 12 Interestingly, the most recent of these studies was a multi-center study that found more generalist visits, hospital admissions and Emergency Room visits among Black and Hispanic patients, but determined these effects to be dependent on the site of treatment. 11 One of the sites in this study catered to a largely middle-class population, while three other sites served a lower socio-demographic population. Controlling for the site in the statistical model decreased the magnitudes and significance of the observed sociodemographic disparities substantially. It would appear that there is more to the apparent socio-demographic disparity in epilepsy care than race and income per se: the authors suggest that there could be unmeasured clinical/personal patient characteristics such as seizure severity or patient attitudes and beliefs influencing treatment outcomes. 11 Such a site-to-site disparity could explain why we did not find a difference in seizure control based on race or family income in contrast to some of the other previous reports. A 'neighborhood-level effect' on health-care disparities has also been reported for other disease conditions such as HIV treatment 32 and cardiovascular care. 33 Moreover, in our study, analysis of seizure control against household income independent of race did not show a significant difference. Previous studies have shown worse control of disease in poor patients with epilepsy. 11 Our findings are thus relevant in demonstrating that socio-demographic disparity is not universal as other recent research has suggested. It would be interesting to see if treatment at a comprehensive epilepsy center may have contributed to an improved outcome in African-Americans and low income groups leading to a negation of the previously reported race effect on epilepsy control. The geographic locations that comprise the catchment area of our outpatient clinic would lead to some homogeneity of socio-economic factors between groups. Moreover, even though there was no insurance-based disparity in average household income, there was a significant difference in income based on race (African-Americans vs. Caucasians), which also did not result in a difference in seizure control.
Anti-epileptic drugs
Unsurprisingly, we found an association between poor seizure control and greater number of AEDs used: patients with poor seizure control would be expected to be on a larger number of medications. Further analysis did not reveal an association between medication cost and seizure control. It should be noted that medication costs do not accurately reflect treatment intensity due to potential non-compliance and wide variability in AED costs. PWE who are poor are likely to be non-compliant with medications, likely due to inability to afford medications. 34 
Insurance
There is a perception among Neurologists of variability in the ease of obtaining the prescribed AED or brand name formulations depending on insurance type, potentially affecting seizure control. Most American citizens receive health insurance coverage through the private sector. Public sector programs exist to provide health insurance to citizens that meet certain eligibility requirements and also for those who cannot obtain private health insurance. Medicare is a federally-funded insurance program largely for citizens of age 65 years and older. Medicaid, by contrast, is funded both by federal and state governments, and provides health insurance to citizens that fall below a certain income and asset baseline. Few studies have assessed how the type of insurance affects epilepsy treatment and outcomes. We did not find an association between the type of insurance (Medicare, Medicaid or Private) and cost of AED prescribed or seizure control. Uninsured patients have been reported to be less compliant with antiepileptic drug therapy compared to patients with insurance. 8 In a study assessing patients with seizures presenting to the Emergency Room, only 39% were found to have any insurance other than state coverage. 9 Compared to private insurance, Medicare coverage was found to be associated with an increased likelihood in attending the Emergency Room or getting admitted to the hospital. 11 To our knowledge, these are the only studies which investigated how the type of insurance affects epilepsy treatment. It has not been documented whether insurance company policies affect the AED prescribed or seizure control. We could not specifically examine whether patients on particular types of insurance were more likely to get brand versus generic medications. Some studies have reported better seizure control with brand, as opposed to generic, medications. 35, 36 However, if particular insurance types were more likely to approve brand name medications, the effect was not measurably translated into eventual outcomes as we did not find an association between insurance type and seizure control. We also did not find an association between family income and insurance type.
Limitations
The study had limitations intrinsic to retrospective studies. We used strict inclusion criteria to include only patients in whom all the relevant information was available to minimize these limitations. This study has been unable to determine the relationship between certain races and treatment outcomes, which were not included in this study. These included Hispanics and Asians, for whom we lacked a large enough sample size to provide meaningful statistical analysis. Although Hispanics formed about 13% of the population in the city of Philadelphia as per the 2010 US census, in the center city area, where our hospital is located, they constitute only about 3-8% of the population. Another potential reason for underrepresentation of certain racial subgroups may be their limited access to organized healthcare. It is possible that particularly adverse socioeconomic status and consequent limitations in access to quality healthcare affects outcomes, including epilepsy control, in these subgroups. It is unclear how these patient groups can be better represented in the literature, so that the problems they face are better documented and solutions sought. Multicenter studies could suffer from similar shortcomings. Population surveys may provide some information, but it would be impractical to collect detailed information for every clinical condition. Many previous surveys including the NHANES (National Health and Nutrition Examination Survey) in the USA have, perhaps justifiably, paid greatest attention to cardiovascular disease. Perhaps the selection of epilepsy as an additional ''focus area'' in future large surveys may clarify some of these issues. Local socio-cultural factors including compliance and attitudes towards treatment may affect treatment outcome 32, 33 which could limit the generalizability of our results. However it is still important to document that there are specialized subpopulations that have a different socio-demographic effect on seizure control than larger population studies. Determining the factors responsible for such a disparity such as treatment at specialized epilepsy centers could guide future policy. Our patient population of more refractory epilepsy also limits generalization of our results. Although the cost of medications prescribed and seizure control were similar in all income groups, it is possible that compliance may have differed based on social or economic factors. 8 A potential advantage of the use of brand name medications over generics 35, 36 could not be evaluated in our analysis. In our study, the numbers of PWE having different types of private insurance were too small to assess treatment or outcome differences between them.
Conclusions
We find that in our population of PWE, there were no significant effects of race or family income on seizure outcome. Our study adds to the existing literature which has mostly found a negative impact of African-American race or poor economic status on various indices of epilepsy epidemiology, treatment and outcome. Our findings are in line with recent research which has uncovered site-specific variability in these indices. 11 Further exploration of these measures by other groups is essential in providing a broader vision of the status of socio-demographic disparities in epilepsy care. Uncovering specific causes of site-to-site variability of the socio-economic impact on seizure control may help guide health care policy.
